贵州百灵Y101受追捧幕后:合作方研发乙
贵州百灵Y101受追捧幕后:合作方研发乙: 当日历翻到2009年3月时,贵州百灵开始正式介入Y101项目,它与天津药物研究院等签订了《技术合作开发合同》,即承担Y101项目临床前研究及相关专利技术转让费共3000万元,同时明确约定项目专利、获得 ...
Updates & Legacy — Stigmabase is a Canadian Non-Governmental & Nonprofit Initiative. Our mission is to inform about stigma around the world and make the data collected accessible for researchers. Stigmabase is very attentive to misinformation and lists only reliable sources. — The marginalization of individuals or categories of individuals is a too common phenomenon. Millions of people are facing this problem around the world and many complex factors are involved.